Alex Zisson (Partner, Thomas, McNerney & Partners and Director, Clarus Therapeutics, Inc.). Mr. Zisson joined Thomas, McNerney & Partners in 2002. In addition to being a Director of Clarus, he also is a board member of Tranzyme Pharma, Inc. , Quinnova Pharmaceuticals, Inc. and Zogenix, Inc. Before joining the firm, he spent eleven years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Mr. Zisson led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. He was the lead analyst on 10 book-running IPOs and 20 book-run secondary offerings, raising over $2 billion for health care companies. In 1997, he was named a Managing Director and began assuming management responsibilities for the health care research group and the firm's annual January conference. After the merger of Chase H&Q and JPMorgan, Mr. Zisson became the firm's Health Care Strategist. He was named twice in The Wall Street Journal’s All-Star Analysts Survey, including during his last year at JPMorgan when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and 'home run' hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.

Thomas, McNerney & Partners

<< Back